A company in Bokeo, which holds a garbage collection concession from the government, was recently found to be collecting fees in Thai Baht. This incident highlights the challenges faced by the Lao government in controlling the use of foreign currency within the country.
Company in Bokeo Collects Garbage Fees in Baht as Kip Continues Depreciating
ROSEN, LEADING INVESTOR COUNSEL, Encourages DouYu International Holdings Limited Investors to Secure Counsel Before Important Deadline in the Securities Class Action First Filed by the Firm – DOYU
New York, New York – Newsfile Corp. – July 6, 2023 – WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of DouYu International Holdings Limited (NASDAQ: DOYU) between April 30, 2021 and May 9, 2023, both dates inclusive (the “Class Period”) of the important August 8, 2023 lead plaintiff deadline in the securities class action first filed by the Firm. 
SO WHAT: If you purchased DouYu securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the DouYu class action, go to https://rosenlegal.com/submit-form/?case_id=15999 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 8, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose, among other things, that: (1) The Chinese government, due to concerns about issues such as video game and computer addiction, as well as content challenging its authority, could become increasingly aggressive towards DouYu regardless of how effective or sincere its attempts to comply with Chinese law were; (2) this increasingly aggressive posture subjected DouYu to a heightened risk of an investigation and subsequent government enforcement action and ultimately resulted in enforcement action; and (3) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the DouYu class action, go to https://rosenlegal.com/submit-form/?case_id=15999 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
——————————-
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com
The issuer is solely responsible for the content of this announcement.
O&G Specialist Clinic Expands Egg Freezing Services In Line With Updated Regulations
SINGAPORE – Media OutReach – 7 July 2023 – The O&G Specialist Clinic, a leading IVF clinic in Singapore, is pleased to announce the expansion of its Egg Freezing services to more groups of women. This is in line with the legislation of Elective Egg Freezing in Singapore. Starting from 1 July, women in Singapore aged 21 to 37 are no longer limited to undergoing Egg Freezing solely for medical reasons but can now do so under personal circumstances.
Egg Freezing is a complex and delicate process that can only be carried out by specialised medical professionals, a service offered by The O&G Specialist Clinic. From ovarian monitoring and egg retrieval to laboratory handling and genetic testing, Egg Freezing entails many critical steps that require a deep understanding of reproductive physiology. Egg Freezing is also a personalised treatment that sees patients receiving careful evaluation and planning based on their medical history, hormone levels, ovarian reserve, and overall health. The esteemed doctors at The O&G Specialist Clinic are highly experienced in this area of treatment and will employ their expertise throughout the procedure.
The O&G Specialist Clinic is founded by Dr. Loh Seong Feei, a renowned Infertility Management and O&G Specialist and Surgeon with over 30 years of experience. Dr. Loh is currently the Medical Director of Thomson Fertility Centre and has previously headed the Department of Reproductive Medicine at KK Women’s and Children’s Hospital where he was also the Director of KKIVF Centre. He is joined by Dr. Janice Tung, an IVF-accredited specialist, who has over 12 years of medical experience in the public and private care sector. Aside from Egg Freezing, other specialised services provided by The O&G Specialist Clinic include In vitro Fertilisation (IVF), Intrauterine Insemination (IUI) treatment in Singapore and care for pregnancy and women’s health.
One of the main objectives that The O&G Specialist Clinic constantly seeks to achieve is to deliver tailored fertility treatments which are patient-centred and patient-friendly. The clinic’s Egg Freezing Package is now available to a wider range of female patients, and appointments can be scheduled either at the clinic or through virtual consultation.
For more information, please visit https://ogclinic.com.sg/.
Hashtag: #O&GSpecialistClinic #EggFreezing #IVFClinic
The issuer is solely responsible for the content of this announcement.
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Cutera, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – CUTR
New York, New York – Newsfile Corp. – July 6, 2023 – WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cutera, Inc. (NASDAQ: CUTR) between February 17, 2021 and May 9, 2023, both dates inclusive (the “Class Period”) of the important July 24, 2023 lead plaintiff deadline. 
SO WHAT: If you purchased Cutera securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Cutera class action, go to https://rosenlegal.com/submit-form/?case_id=16520 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 24, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) overstated the sustainability of Cutera’s revenue growth; (2) failed to disclose significant conflicts among members of the Company’s senior leadership and Board; (3) failed to disclose several material weaknesses in the Company’s internal control over financial reporting; and (4) as a result of the foregoing, and the significant decline in the market value of the Company’s common stock, Plaintiff and other members of the Class suffered significant damages. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Cutera class action, go to https://rosenlegal.com/submit-form/?case_id=16520 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
——————————-
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com
The issuer is solely responsible for the content of this announcement.
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Microvast Holdings, Inc. Investors With Losses to Inquire About Securities Class Action Investigation – MVST, MVSTW
New York, New York – Newsfile Corp. – July 6, 2023 – WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Microvast Holdings, Inc. (NASDAQ: MVST) (NASDAQ: MVSTW) resulting from allegations that Microvast may have issued materially misleading business information to the investing public. 
SO WHAT: If you purchased Microvast securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=16538 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.
WHAT IS THIS ABOUT: On May 22, 2023, Reuters reported that the U.S. Department of Energy (DoE) canceled a $200M grant to lithium battery manufacturer, Microvast, citing lawmakers’ concerns over Microvast’s alleged links to the Chinese Communist Party. Microvast has been in talks with the DoE over the grant to help build a plant in Tennessee to support its work with General Motors developing specialized electric vehicle batteries.
On this news, Microvast’s stock price fell $0.80 per share, or 36.36% to close at $1.40 per share on May 23, 2023.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
——————————-
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com
The issuer is solely responsible for the content of this announcement.
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages JinkoSolar Holding Co., Ltd. Investors to Inquire About Securities Class Action Investigation – JKS
New York, New York – Newsfile Corp. – July 6, 2023 – WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of JinkoSolar Holding Co., Ltd (NYSE: JKS) resulting from allegations that JinkoSolar may have issued materially misleading business information to the investing public. 
SO WHAT: If you purchased JinkoSolar securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=16025 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.
WHAT IS THIS ABOUT: On May 9, 2023, before trading hours, the Jacksonville Daily Record published an article entitled “Federal agents issue search warrant at JinkoSolar plant in Cecil Commerce Center: Homeland Security said it is part of an ongoing investigation; the factory, whose parent company is in China, opened in Jacksonville in 2018.” The Jacksonville Daily Record reported that “[a]ccording to the Federal Bureau of Investigation, federal agents were assisting the Department of Homeland Security with the execution of a search warrant.” Further, the article cited WJXT News4Jax, stating that JinkoSolar is one of several companies under investigation by the U.S. Commerce Department for circumventing trade rules by sending products to other countries before moving them to the U.S.
On this news, JinkoSolar’s American depositary receipt (“ADR”) price fell $3.91 per ADR, or 8%, to close at $43.47 per ADR on May 9, 2023, on unusually heavy trading volume.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
——————————-
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com
The issuer is solely responsible for the content of this announcement.
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Fox Corporation Investors to Inquire About Securities Class Action Investigation – FOX, FOXA
New York, New York – Newsfile Corp. – July 6, 2023 – WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Fox Corporation (NASDAQ: FOX) (NASDAQ: FOXA) resulting from allegations that FOX may have issued materially misleading business information to the investing public. The prospective class includes those who purchased FOX call options and/or sold put options. 
SO WHAT: If you purchased FOX securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=13327 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.
WHAT IS THIS ABOUT: In the wake of the 2020 U.S. Presidential Election, Dominion Voting Systems sued FOX for defamation. Dominion’s lawsuit alleges that FOX defamed Dominion’s business by endorsing, repeating or broadcasting a series of “verifiably false yet devastating lies about Dominion.” Dominion claims that various statements that were made on FOX News, including that Dominion committed election fraud by rigging the 2020 election, that Dominion’s software and algorithms manipulated vote counts in the 2020 election, that Dominion was founded for the purpose of rigging elections, and that Dominion paid kickbacks to government officials who used its machines, were defamatory and false. Dominion and Fox eventually agreed to settle the case for $787 million.
Beginning in February 2023, specific details emerged of internal discussions at FOX in the wake of the 2020 election, revealing that FOX’s senior leaders understood that claims to the effect that Dominion and other entities had rigged the 2020 election were false. As a consequence, FOX faces significant potential legal liability.
As a result of ongoing revelations about FOX’s legal exposure in the Dominion lawsuit, FOX’s Class A stock has declined from a closing price of $37.03 on February 17, 2023 to a closing price of $32.52 on March 15, 2023, a 12% decline. FOX’s Class B stock has declined from a closing price of $34.22 on February 17, 2023 to a closing price of $29.83 on March 15, 2023, a 12% decline.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
——————————-
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com
The issuer is solely responsible for the content of this announcement.
Secarna Pharmaceuticals publishes new preclinical data in The Journal of Immunology demonstrating potent therapeutic activity of LNAplus™ ASO targeting NLRP3 in highly debilitating autoinflammatory diseases
- Secarna’s LNAplus™ ASOs suppress expression of NLRP3, a central component of the inflammasome pathway, which is overactive in many inflammatory diseases
- Cryopyrin-associated periodic syndrome (CAPS) is a group of rare inherited autoinflammatory diseases driven by overactive NLRP3, resulting in systemic inflammation
- With NLRP3-specific ASOs, inflammatory downstream effects were interrupted in immune cells and strong symptom relief and significant prolongation of survival was achieved in a CAPS disease model.
MUNICH/MARTINSRIED, GERMANY – EQS Newswire – 6 July 2023 – Secarna Pharmaceuticals GmbH & Co. KG (“Secarna”), a biopharmaceutical company focusing on the discovery and development of next-generation antisense oligonucleotide (ASO) therapies to address challenging or previously undruggable targets via its LNAplus™ platform, announced today the publication of compelling new preclinical data supporting the use of ASOs for the treatment of inflammatory diseases in the peer-reviewed journal, The Journal of Immunology. The article, “Antisense oligonucleotide therapy decreases IL-1β expression and prolongs survival in mutant Nlrp3 mice”, addresses the joint work of the groups of Prof. Ariel Feldstein and Prof. Hal Hoffman from the University of California San Diego, world-leading specialists in the field of NLRP3-mediated inflammation and CAPS, and Secarna and can be found here.
Using its proprietary Oligofyer™ bioinformatics system, Secarna designed LNAplus™ ASOs to specifically suppress the expression of the NLR family pyrin domain containing 3 (NLRP3), the central component of the inflammasome pathway. Activation of the inflammasome results in release of proinflammatory cytokines such as IL-1β. Overactivation of this pathway has a pathological role in many diseases with an inflammatory component, such as arthritis, inflammatory bowel disease, acute and chronic kidney disease, non-alcoholic steatohepatitis, asthma and also diseases of the central nervous system, such as Parkinson’s disease and Alzheimer’s disease. The results of this study demonstrate that NLRP3-specific ASO treatment downregulates NLRP3 expression and IL-1β release in the CAPS disease model, suggesting ASO therapy as a potential treatment of CAPS or other NLRP3-mediated diseases.
CAPS are a spectrum of autoinflammatory diseases caused by activating mutations in the NLRP3 gene. Depending on the type of mutation, symptoms and disease severity, they are divided into neonatal onset multisystem inflammatory disease (NOMID), Muckle Wells syndrome (MWS), and familial cold autoinflammatory syndrome (FCAS). Symptoms are heterogeneous and can include fever, urticarial rash but also multiple neurological manifestations that can be debilitating and have a severe impact on quality of life. Current therapies have been designed to inhibit the IL-1β pathway and have been shown to improve clinical symptoms in patients. However, there remains an unmet clinical need for patients who do not respond adequately, emphasizing the need for improved therapies.
“With the publication of these preclinical results, we have demonstrated that NLRP3-specific ASOs can effectively target this gene across the CAPS spectrum and therefore block the overactivation of the inflammatory cascade,” said Frank Jaschinski, Ph.D., Chief Scientific Officer of Secarna Pharmaceuticals. “We are excited to see that in a particularly aggressive model of CAPS clear therapeutic benefits on different readouts in relevant organs were achieved by NLRP3-ASO treatment. Furthermore, the data open the door for these ASOs to treat other diseases driven by an overactive NLRP3 inflammasome pathway, such as inflammatory bowel disease, acute and chronic kidney disease, and diseases of the central nervous system. I very much look forward to seeing the development of ASOs targeting inflammation, a field where, to date, there is no approved ASO treatment.”
The groups from the University of California San Diego tested the potential of the NLRP3-ASOs for treatment of CAPS in in vitro and in vivo models. In cell culture they demonstrated that NLRP3-ASOs potently suppressed expression of the gene. Furthermore, there was a strong reduction in the secretion of the proinflammatory cytokine IL-1β in immune cell cultures derived from in vivo models from all three types of CAPS. The activity of NLRP3-ASO was tested in an in vivo NOMID disease model; NOMID is the most severe form of CAPS. After systemic ASO treatment, life expectancy was significantly increased, with weight gains and reductions in the severity of skin lesions, showing an overall reduction in systemic inflammation.
Hashtag: #SecarnaPharmaceuticals
The issuer is solely responsible for the content of this announcement.
About Secarna’s proprietary drug discovery and development platform, LNAplus™
Secarna’s proprietary, customized LNAplus™ platform is being applied to the discovery, testing and selection of antisense oligonucleotides (ASOs) for pre-clinical and clinical development. LNAplus™ encompasses all aspects of drug discovery and pre-clinical development and has proven to be fast, reliable, scalable and efficient, enabling the discovery of novel antisense-based therapies for challenging or currently undruggable targets. The platform includes the powerful proprietary Oligofyer™ bioinformatics pipeline, a streamlined, high efficiency screening process, including Secarna’s proprietary LNA-Vit(r)ox™ safety test system, as well as target-specific functional assays. Secarna’s platform and ASOs have been validated by numerous in-house projects as well as in several academic and industry collaborations.
About Secarna Pharmaceuticals GmbH & Co. KG
Secarna Pharmaceuticals is the leading independent European next-generation antisense drug discovery and development company addressing high unmet medical needs in immuno-oncology and immunology, as well as viral, neurodegenerative and cardiometabolic diseases. Secarna’s mission is to maximize the performance and output of its proprietary LNAplus™ antisense oligonucleotide discovery platform, as well as to develop highly specific, safe, and efficacious best-in-class antisense therapies. With over 20 discovery and development programs, including both proprietary pipeline projects and partnered programs, Secarna focuses on targets in indications where antisense-based approaches have clear potential benefits over other therapeutic modalities. 
www.secarna.com
